TrialJapanese journal of clinical oncology2020

Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.

Dai Maruyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.